New hope for kids with arthritis: real-world study tests tofacitinib

NCT ID NCT07211932

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study looks at how well the drug tofacitinib works for children with juvenile idiopathic arthritis (JIA). Researchers will use real-world medical records from 58 children under 18 to see if the drug improves arthritis control after 12 months. The goal is to reduce disease activity and help kids feel better, but ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Corporació Sanitària Parc Taulí de Sabadell

    Sabadell, Barcelona, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital Sant Joan de Déu Barcelona

    Barcelona, Barcelona, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital de Vilafranca

    Vilafranca del Penedès, Barceona, 08720, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.